Pamela Z. Cacchione 1
The protection of human subjects is the responsibility of the principal investigator (PI), institutional review board (IRB) and the funding agency. The National Institutes of Health, the European Medicines Agency, the British National Health Service Health Technology Assessment Program, and the U.S. Food and Drug Administration all expect clinical trials involving human subjects to have a data and safety monitoring (DSM) plan to ensure the ongoing safety of participants as well as the ongoing scientific merit of the trial (Hicks, Laupacis, & Slutsky, 2007;  Office for Protection of Research Subjects [OPRS], 2009) . Clinical trials involving human subjects fall into one of three "phases" of research. Phase I trials include physiologic, toxicity, and dose finding studies and typically include small numbers of participants with a high level of risk. Phase II trials include efficacy studies that often test an intervention on a larger group of participants. Phase III trials include efficacy, effectiveness, and comparative trials that often have even larger groups of participants over longer periods of time (National Institute of Health [NIH], 1998; National Institute on Deafness and Other Communication Disorders [NIDCD], 2010). NIH's Policy for DSM (1998) stated that the "Institutional Review Boards and NIH must ensure to the extent possible, the safety of the study participants, that they do not incur undue risk, and that the risk versus benefits are continually reassessed throughout the study period" (p. 1).
The extent of the DSM required will depend on the phase and complexity of the study. The DSM may range from a DSM plan developed and maintained by the PI to an external independent DSM board that monitors multisite studies. NIH requires DSM in the form of a DSM board for all Phase III clinical trials (NIDCD, 2010) . Some of the institutes within NIH convene DSM boards depending on the study, the level of risk, and funding mechanism (National Heart Lung and Blood Institute, 2007) . When developing a research proposal, the PI should determine what type of study is being proposed and then determine what type of DSM is warranted. NIH has provided a decision tree that aids the PI in determining if a DSM board is required for NIH funded studies. The decision tree can be found at http://funding.niaid.nih.gov/ncn/clinical/ decisiontrees/datasafety.htm.
Clinical trials with human subjects at the very least require a DSM plan that describes (a) who is responsible for the data monitoring and the subject safety monitoring; (b) how and to whom adverse events are reported to and monitored; and (c) how this plan fits the level of risk to the participants, complexity of the study, and the methods of data analysis (National Institute of Allergy, Infectious Disease, 2009). If the plan includes all these elements and is consistent with needs of the study and is clearly described, per the decision tree, the DSM plan should be deemed acceptable. If the PI is not sure about what the most appropriate level of DSM is necessary for their study, they can contact their IRB or the funding agency.
A DSM plan is part of the research protocol that describes how the PI will ensure the safety of the participants as well as the validity of the data (OPRS, 2009 ). This plan should include a description of how the PI will monitor and ensure the progress of the study as well as the safety of the study participants. The PI should include in the plan how unexpected events and adverse events will be monitored and addressed if needed. The data auditing and monitoring should also be addressed. For example, how interrater reliability will be maintained, and how the accuracy of the data entry will be determined throughout the study should be described in the DSM plan.
For clinical trials with a complex intervention and/or with a vulnerable population, such as older adults with cognitive impairment, an external DSM board may be indicted with at least three members who have different types of expertise. Ideally, if the study was working with older adults with cognitive impairment, an expert who has done research with older adults with cognitive impairment should be on the board, and the board would also benefit by a statistician and someone who is familiar with the type of intervention being investigated. If possible, the members would not all be from the PI's institution, but at the very least they should not be from the same school within the PI's institution. There also should not be a conflict of interest between the PI and the members of the board (Hicks et al., 2007) . Feedback from the DSM board that might be expected could be suggestions on consent process and involvement of the responsible parties. The DSM board may also comment on any adverse events that occur and provide guidance as to the continuation of the study. The DSM board is also charged with identifying whether the impact to the intervention is so positive that it should be stopped early and moved forward in dissemination to the public.
In my own research, which involved older adults with varying levels of cognitive impairment, my DSM board provided feedback on the consent process and the notification of the responsible parties once a participant had agreed to participate that went beyond what the IRB required but provided an extra-assurance that the participants' safety was not at risk. The DSM board also provided suggestions for documentation of research visits and adverse events in the participants' medical records. Both these suggestions were beyond the IRB's requirements but within the realm of keeping the participants' safety within the research protocol. The DSM board was also notified of all adverse events whether they were thought to be related to the research protocol. The board helped confirm that the adverse events were not related to the research protocol. When it was found that the adverse events-for example, bleeding in the ear canal after cerumen removal-was due to the research protocol, this was added to the consent form, and a change of protocol was submitted to the IRB. When an unanticipated event was large enough to interfere with the progression of the study, the funding agency should be notified. For example, in my study a natural disaster caused an evacuation of one of the research sites. This evacuation event was shared with National Institute of Nursing Research and the DSM board. The decision was made to withdraw the study from this site. Again, a change in protocol to the IRB was submitted documenting this event as well.
In the case of a multisite clinical trial, a more sophisticated data monitoring board may be required where all adverse events and serious adverse events from all sites can be sent for safety monitoring. Sophisticated DSM boards also have individuals who tour the research sites to perform audits for DSM not only to assure the safety of the participants but also to assure the quality of the data. Pharmaceutical trials often use these more sophisticated methods for DSM. However, this type of DSM board could be used in a complex multisite study testing a nursing intervention. The benefits of this type of DSM board are that one central location receives all of the adverse events, patterns can be identified early, and notices or announcements can be directed from the DSM board to the PI's of each site and to the overall primary investigator in order for changes in the protocol to be made or, in extreme cases, for the project to halt.
It is important to keep in mind that DSM boards are advisory boards that report to the PI and possibly the sponsor of the research, but their work is on behalf of the study participants and the broader public (Hicks et al., 2007) . There is significant value in having impartial experts in the methodologies being used, the topic or intervention of interest and the population being studied to aid in the safety and validity of the research being undertaken. The goal of these advisory boards is to avoid placing the participants at undue risk and to be able to demonstrate a valid benefit from participation in the research. Working with a DSM board has the added benefit to the researcher of increasing the validity of the study's findings.
